Increase in the ATP signal after treatment with cisplatin in two different cell lines studied by 31P NMR spectroscopy.

We have compared the 31P nuclear magnetic resonance (NMR) spectra of two different cisplatin resistant cell lines, one derived from human ovarian carcinoma and the other from rat lymphoma, and their respective cisplatin sensitive parental cell lines. Comparisons were made between the baseline spectra and after perfusion of the cells with 20-50 microM cisplatin for 16-20 hours. While no obvious differences were found between baseline spectra of sensitive and resistant cells, during cisplatin perfusion the sensitive cells had an increase in their ATP signals. The resistant cells also exhibited increases in their ATP signals during cisplatin perfusion but to a lesser extent than the sensitive cells. Although the significance of these ATP elevations towards the cellular pharmacology of cisplatin are not presently known, our studies demonstrate that 31P NMR spectroscopy may be useful for elucidating differences in phosphate metabolism in cells expressing the cisplatin resistant phenotype.

[1]  M. Gottesman,et al.  The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. , 1991, Cancer research.

[2]  J. S. Cohen,et al.  Multinuclear NMR Study of the Metabolism of Drug‐Sensitive and Drug‐Resistant Human Breast Cancer Cells , 1987, Annals of the New York Academy of Sciences.

[3]  S. Howell,et al.  Modulation of cis‐diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3‐isobutyl‐1‐methylxanthine in sensitive and resistant human ovarian carcinoma cells , 1991, International journal of cancer.

[4]  J. Mazurkiewicz,et al.  A morphological and phenotypic analysis of Walker 256 cells. , 1991, Cancer research.

[5]  D L Foxall,et al.  Continuous perfusion of mammalian cells embedded in agarose gel threads. , 1984, Experimental cell research.

[6]  I. Edwards,et al.  cis-Platinum: subcellular distribution and binding to cytosolic ligands. , 1983, Biochemical pharmacology.

[7]  Steen Rg,et al.  Response of solid tumors to chemotherapy monitored by in vivo 31P nuclear magnetic resonance spectroscopy: a review. , 1989 .

[8]  S. Lippard,et al.  Structural aspects of platinum anticancer drug interactions with DNA , 1987 .

[9]  R. Steen,et al.  31P and 1H NMR Spectroscopy of Tumors in Vivo: Untreated Growth and Response to Chemotherapy , 1987, Annals of the New York Academy of Sciences.

[10]  W. D. de Jong,et al.  31P NMR study of cisplatin‐ and doxorubicininduced changes in tumour metabolism in rats with a cisplatin‐sensitive or ‐resistant immunocytoma , 1990, NMR in biomedicine.

[11]  P. V. van Zijl,et al.  Information from combined 1H and 31P NMR studies of cell extracts: differences in metabolism between drug-sensitive and drug-resistant MCF-7 human breast cancer cells. , 1990, Biochemical and biophysical research communications.

[12]  G. Zugmaier,et al.  Regulation of the cytidine phospholipid pathways in human cancer cells and effects of 1-beta-D-arabinofuranosylcytosine: a noninvasive 31P nuclear magnetic resonance study. , 1990, Cancer research.

[13]  K. Wolf,et al.  31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance. , 1991, British Journal of Cancer.

[14]  R. D. Dyer,et al.  Protein analysis with bicinchoninic acid. , 1988, Annals of clinical and laboratory science.

[15]  Studies of the metabolism of human breast cancer spheroids by NMR , 1989, Magnetic resonance in medicine.

[16]  R. Lyon,et al.  Monitoring intracellular metabolism by nuclear magnetic resonance. , 1989, Methods in enzymology.

[17]  F. Muggia.  Cancer and hypercalcemia of malignancy: a change in focus. , 1991, Seminars in oncology.